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Abstract
Background: In the Netherlands, perinatal asphyxia (severe perinatal oxygen shortage) necessitating newborn
resuscitation occurs in at least 200 of the 180–185.000 newly born infants per year. International randomized controlled
trials have demonstrated an improved neurological outcome with therapeutic hypothermia. During hypothermia
neonates receive sedative, analgesic, anti-epileptic and antibiotic drugs. So far little information is available how the
pharmacokinetics (PK) and pharmacodynamics (PD) of these drugs are influenced by post resuscitation multi organ
failure and the metabolic effects of the cooling treatment itself. As a result, evidence based dosing guidelines are
lacking. This multicenter observational cohort study was designed to answer the question how hypothermia influences
the distribution, metabolism and elimination of commonly used drugs in neonatal intensive care.
Methods/Design: Multicenter cohort study. All term neonates treated with hypothermia for Hypoxic Ischemic
Encephalopathy (HIE) resulting from perinatal asphyxia in all ten Dutch Neonatal Intensive Care Units (NICUs) will be
eligible for this study. During hypothermia and rewarming blood samples will be taken from indwelling catheters to
investigate blood concentrations of several antibiotics, analgesics, sedatives and anti-epileptic drugs. For each individual
drug the population PK will be characterized using Nonlinear Mixed Effects Modelling (NONMEM). It will be investigated
how clearance and volume of distribution are influenced by hypothermia also taking maturation of neonate into
account. Similarly, integrated PK-PD models will be developed relating the time course of drug concentration to
pharmacodynamic parameters such as successful seizure treatment; pain assessment and infection clearance.
Discussion: On basis of the derived population PK-PD models dosing guidelines will be developed for the application
of drugs during neonatal hypothermia treatment. The results of this study will lead to an evidence based drug
treatment of hypothermic neonatal patients. Results will be published in a national web based evidence based
paediatric formulary, peer reviewed journals and international paediatric drug references.
Trial registration: NTR2529.
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In the Netherlands, perinatal asphyxia (severe perinatal
oxygen shortage) occurs in at least 200 out of 180–
185.000 born infants/year. Term neonates experiencing a
severe hypoxic-ischemic insult during birth may develop
hypoxic ischemic encephalopathy (HIE) within hours.
There is a high risk for long term neurological sequelae
such as cerebral palsy, psychomotor retardation, and
visual or auditory handicaps leading to long-term health-
care costs [1,2].
Cerebral hypoxia and ischemia result in several adverse
biochemical events such as increased levels of excitatory
neurotransmitters, excessive free radical production, an in-
crease in intracellular calcium, and secretion of inflamma-
tory mediators and messengers by microglial cells in the
central nervous system initiating neuronal cell death [3-5].
Supportive treatment in the Neonatal Intensive Care
Unit (NICU) comprises mechanical ventilation, cardiovas-
cular support, and treatment of infections and seizures [6].
Animal research on controlled hypothermia following
perinatal asphyxia showed a reduction in cerebral free
radical and inflammatory damage [4,5]. Recent large ran-
domized controlled trials and Meta analyses concerning
the neuroprotective effects of hypothermia treatment in
human asphyxiated neonates demonstrated a statistically
significant and clinically important improvement of long
term outcome [6-13]. Since 2008, all ten NICUs in the
Netherlands have adopted controlled hypothermia as the
standard of care for newborns suffering perinatal asphyxia.
Unfortunately, the potential benefits of therapeutic
hypothermia could potentially be offset by decreased re-
sponsiveness to drug therapy and the occurrence of side
effects due to the altered pharmacokinetics (PK) and
pharmacodynamics (PD) during hypothermia [14,15].
Frequently used life-saving drugs in these newborns are
sedatives, analgesics, antibiotics, and antiepileptic drugs
(AED) and toxic side effects of these agents (e.g. cardiac
arrhythmias from lidocaine; prolonged sedative effects
from midazolam or morphine; nephrotoxicity –or oto-
toxicity for aminoglycosides) must be prevented.
There is evidence that the application of mild to mod-
erate hypothermia decreases the systemic clearance of
drugs metabolized by cytochrome P450 enzymes be-
tween approximately 7% and 22% per degree Celsius
below 37°C [16].
The effects of hypothermia on drug metabolism have
been investigated in humans but few studies concern
drug metabolism in asphyxiated newborns. Sedatives
and AEDs are important drugs used in the care of
asphyxiated newborns. A decreased elimination rate con-
stant (Ke) and clearance (CL) of midazolam was demon-
strated during hypothermia in adult volunteers [17] but
data on cooled neonatal patients are unknown. Recent
findings suggest that phenytoin metabolism is inhibited
by mild therapeutic hypothermia [18]. The administra-
tion of phenobarbital to newborns under whole body
hypothermia has been reported to result in higher
plasma concentrations when compared to normothermic
newborns [19]. In non-cooled newborns an optimal lido-
caine dosage schedule has been established [20], but the
PK during cooling are unknown.
Analgesia is of major importance in neonatal intensive
care as inadequate analgesia causes stress, counterpro-
ductive to the neuroprotective actions of hypothermia.
On the other hand, toxic analgesic levels may cause pro-
longed sedative effects interfering with clinical neuro-
logical evaluations. Experimental studies demonstrated a
25% increase in plasma concentration of fentanyl at core
body temperatures of 32°C [21]. Furthermore, Róka
described elevated serum morphine concentrations and
potentially toxic morphine levels in newborns with com-
monly used infusion rates of 10 μg/kg/hour during
hypothermia [22].
Almost all newborns undergoing hypothermia treat-
ment receive multiple antibiotic courses. The PK/PD
properties of aminogycoside and glycopeptide antibiotics
in these patients are largely unknown. The toxicity risks
of gentamicin (nephro- and ototoxicity) in hypothermic
newborns have only been evaluated in one study by
Thorensen and colleagues [23]. A study in three adult
cases concluded that induced hypothermia may result in
impaired excretion of aminoglycosides [24]. The pharmaco-
kinetics of penicillin and beta-lactam during hypothermia
have not been studied yet.
Interestingly, other drugs do not seem to be influenced
by cooling. A recent report concerning infants treated
with the AED topiramate, a drug not licensed for use in
neonates in the Netherlands at present, in a dose of
5 mg/kg/day, demonstrated drug concentrations within
the reference range for the entire cooling treatment
duration [25].
Altered pharmacokinetics during hypothermia may re-
sult in sub therapeutic as well as toxic drug concentra-
tions Since many asphyxiated newborns will be exposed
to controlled hypothermia evidence based guidelines for
drug dosing (including loading and maintenance dose and
dose interval) and therapeutic drug monitoring are ur-
gently needed. The consequences of possible serious side
effects or sub therapeutic dosing may have an unknown
impact on survival or long term outcome of these infants.
In this Dutch multicenter study it will be investigated
how controlled hypothermia influences the PK and PD
time profiles of four major drug classes (i.e. analgesics,
sedatives; antibiotic and antiepileptic drugs) used in the
intensive care treatment of infants suffering perinatal as-
phyxia. Funding for this study has been received by the
Dutch Government (ZonMw Grant number: 40-41500-
98-9002).
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A multicenter prospective cohort study in ten Dutch ter-
tiary NICUs treating asphyxiated newborns with controlled
hypothermia. Plasma concentrations of analgesic, antiepi-
leptic, sedative and antibiotic drugs will be measured and
used for population PK analysis to develop adjusted dosage
regimens. Furthermore, the association of plasma drug
concentrations with clinical effect will be investigated.
Project management, data management and safety
monitoring
A multicenter setup with a centralised study coordi-
nation and data management has been initiated. This will
provide efficient use of existing resources and knowl-
edge. All local principal investigators will receive GCP
training according to European and international guide-
lines. The recent StaR Child Health Summit held on the
26th and 27th of October 2009 in Amsterdam initiated
further international collaboration on defining GCP stan-
dards for PK/PD research in children. A dedicated clin-
ical project manager will supervise logistics and data
collection during the course of this study. A Clinical
Research Associate (CRA) will conduct monitoring visits
in all participating centres to monitor the adequacy of
data acquisition, the completeness of clinical research
forms (CRF) and the logistics and storage of samples.
Laboratory visits to monitor sample processing and stor-
age will be made every three months.
Serious adverse event policy
The newborns in this study are severely ill and have a high
risk for serious adverse events due to perinatal asphyxia or
multiorgan failure. As no study related interventions will
be performed besides blood sampling, only SAE in relation
to this procedure will be reported to the steering commit-
tee and medical ethics committees of the participating
centers. SAE as demise, severe multiorgan failure, pulmo-
nary hypertension, treatment unresponsive seizures will be
documented as related to the primary illness itself.
If SAEs occur due to unexpected toxic drug concentra-
tions (e.g. severe cardiac symptoms during lidocaine
therapy, prolonged unwanted sedation after midazolam
therapy or renal toxicity in case of aminoglycoside treat-
ment) these will be reported immediately to the steering
committee which will directly communicate the nature
and severity of the SAE to all participating centres.
Database and clinical research file design
Each individual patient participating in this study will
receive an anonimized personal study-identification number
connected with an individual digital Case Record Form
(CRF). Clinical and laboratory data (i.e. obstetric history,
aetiology of asphyxia, Apgar scores, Thompson scores, birth
weight, number of days in need of ventilatory support-or
circulatory support, (co-)medication use, kidney and hepatic
function tests, blood haematology and chemistry results,
imaging results, sedation scores) are recorded in a web-
based database, as well as long term outcome. Web-based
CRFs are completed online by locally authorised and
trained research staff. Participating centers will keep a
written study file on site connecting study identification
numbers with actual hospital identification numbers and
patient files. The CRA fosters the collection of data and
monitors all individual patient data at 3 month intervals.
For this study a web based research database was
developed, which will serve as an instrument to evaluate
the hypothermia treatment, to monitor treatment com-
plications and and to assess long-term outcome of these
critically ill infants. After termination of the study moni-
toring of outcome and complications of the hypothermia
treatment will be continued using this database. Thus
our multicenter national research group, and indirectly
our patients, will continue to benefit from this unique
infrastructure in future research.
Ethics committee approval
The protocol for this observational study has been eval-
uated and approved by the local ethics committees of
the following Dutch Organizations (all 10 NICU’s): The
Academic Medical Centre of Amsterdam; The Erasmus
Medical Centre of Rotterdam; The University Medical
Centre of Utrecht, The Radboud University Nijmegen
Medical Centre; The Maastricht University Medical
Centre; the Maxima Medical Centre Veldhoven; The
Isala Clinics, Zwolle; The Leiden University Medical
Centre, The VU University Medical Centre of Amster-
dam; The University Medical Center Groningen.
Study protocol
Inclusion criteria
Any newborn:
 with a gestational age>36 weeks and a birth
weight>3 kg;
 with Apgar Score at 5 min postnatal<5;
 with continued resuscitation at 10 min postnatal;
 with 1 h postnatal blood gas analysis pH<7.0 or
base deficit>16
 with clinical signs of moderate to severe
encephalopathy (defined as a Thomson score of >7)
 who is undergoing neuroprotective treatment by
controlled hypothermia<6 h postnatal
Exclusion criteria
 congenital hepatic or renal pathology present (as this
makes interpretation of PKPD results impossible);
 no central venous line or arterial bloodstream access
for non-invasive blood sampling procedures
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Treatment protocol
Cooling: According to the national controlled hypothermia
protocol, newborns with a history of perinatal asphyxia
will be cooled to a core body temperature of 33.5°C for 72
h (starting within 6 h after birth). All participating centres
have identical cooling equipment (Criticool Unit, MTRE
Advanced Technologies Ltd, Israel). Following these 72 h
infants will be re-warmed to a normal body temperature.
EEG-MONITORING All newborns will be continu-
ously monitored for seizures by single or multiple lead
aEEG (recorded on the Cerebral Function Monitor). To
evaluate the severity of the encephalopathy aEEG back-
ground patterns will be interpreted according to current
clinical evidence based definitions (Flat-trace, Continuous-
Low-Voltage, Burst-Suppression, Discontinuous Normal
Voltage and Continuous Normal Voltage). Seizure activity
(status, recurrent seizures, incidental seizures) will be
recorded [26]. All infants will also undergo a conventional
full lead EEG during the cooling episode at 48 h following
start of cooling [27].
The type, dosage and number of anti-epileptic drugs
needed to control seizures will be recorded in the CRF.
Clinical encephalopathy scores and sedation
The clinical neurological status of all included newborns
will be evaluated with the Thompson encephalopathy
scores at study entry, during the cooling phase (daily,
during 3 days) and after rewarming [28]. If encephalop-
athy scoring is not possible due to the administration of
sedative drugs, this will be recorded in the CRF. From
study entry on, pain and/or discomfort status of all new-
borns will be evaluated with the neonatal COMFORT
score every 8 h. All changes in the dosing of sedative
and analgesic drugs will be based on either an increase
or decrease in the neonatal COMFORT score [29].
COMFORT scores will be recorded in the CRF.
Blood sampling – routine care
According to the national controlled hypothermia proto-
col all infants will have invasive blood pressure monitor-
ing and central venous lines. All infants will have an
indwelling urine catheter. All blood sampling procedures
will be done on a daily basis according to the existing
clinical protocols of controlled hypothermia. There will
be no additional hematology or blood chemistry analysis
for this study.
The current clinical protocol comprises:
1. Haemoglobin value, leukocytes (count and
differential), thrombocyte count, clotting values (PT,
APTT, fibrinogen).
2. Sodium, potassium, Creatinin, urea, liver enzymes
(ASAT, ALAT, AF, bilirubin, Albumin, lactate, C-
reactive protein.
3. Arterial blood gas analyses (twice daily)
4. Urine analyses: sodium; potassium; osmol; creatinin.
5. Blood cultures before start antibiotic treatment.
Blood sampling – pk/pd analysis
Additional blood samples will be taken for the evaluation
of PK and PD. The sampling times are summarized in
Table 1. No samples will be obtained on day 1 as a
steady hypothermic state will not have been reached.
The samples on day 2 and day 3 will be taken during
the hypothermic state. On day 4 samples will be taken
during rewarming and on day 5 during the steady nor-
mothermic state. In total a volume of 7.2 ml will be
taken from the bloodstream by indwelling arterial cathe-
ters. If these lines are not functioning or cannot be
placed, infants cannot participate in this study. As the
average birth weight of a term newborn is 3.5 kg and the
circulating blood volume is 80 ml/kg (total blood vol-
ume: 280 ml), 7.4 ml will correspond to 2.6% of the total
circulating volume for the whole study. Blood samples
for the evaluation of the PK-PD relationship will be
taken together with clinically indicated blood sampling.
The volume of blood drawn poses no clinical threat for
the infant in terms of circulatory compromise or risk for
anemia.
Dosage of investigated drugs
All investigated drugs are given on clinical indications
and will be administered by the intravenous route. Each
patient will receive usual care during the whole study
period in all participating centers. No dose adaptations
will be made for study purposes. It is the goal of this
study to evaluate the pharmacokinetic profile of cur-
rently used drugs in their current dose schedules. No
new or experimental drugs will be evaluated in this ob-
servational study.
PK/PD analysis
PK and PD data will be analyzed during the normother-
mic and hypothermic state. Three groups of drugs will
Table 1 Time schedule and volumes of PK –blood
sampling
Day 2 Day 3 Day 4 Day 5
07:30 (0.2 ml) + + +
09:00 (0.2 ml) + +
11:00 (0.2 ml) + +
13:00 (1.2 ml) + + + +
15:00 (0.2 ml) + +
19:00 (0.2 ml) + + +
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NICUs:
Group I:
Antibiotics: penicillin, amoxicillin, gentamicin,
amikacin, vancomycin and ceftazidim
Group II:
Analgesics: morphine and fentanyl.
Group III:
Sedative and anti-epileptic drugs: midazolam,
phenobarbital and lidocaine.
For each drug the dose, infusion rate, start time of in-
fusion and end time of infusion are recorded in the CRF.
Blood sampling times are recorded in the CRF as well.
Samples are sent to the central study Pharmacy labora-
tory of the Academic Medical Center in Amsterdam.
The samples will be labelled only with study numbers to
guarantee the privacy of the patient.
State of the art liquid chromatography-mass spectro-
metric (LC-MS/MS) methods will be used to quantita-
tively measure drug concentrations in plasma. By using
LC-MS, concentrations of drugs can be measured simul-
taneously in a small volume of plasma. The simultaneous
quantification minimizes patient blood sampling and
reduces study costs. Analyses of antibiotic plasma levels
will be performed in the Pharmacy laboratory of the
Academic Medical Center in Amsterdam and analyses of
analgesic, AED and sedative plasma levels will be per-
formed in the Pharmacy laboratory of the University
Medical Center in Utrecht, the Netherlands. Analytical
micro-assays has been developed and validated for the
simultaneous analysis of phenobarbital, lidocaine (plus
metabolite MEGX), morphine (plus 3- and 6-glucuro-
nides) and midazolam (plus hydroxymidazolam and glu-
curonide) in 0.5 mL of serum. Simultaneous analysis of
antibiotic drugs will be performed in 0.1 ml plasma.
PK/PD- data analysis
Nonlinear mixed-effects models (NONMEM) will be
used to describe the time course of the drug concentra-
tion in plasma. Application of NONMEM allows average
values for PK parameters as clearance and volume of dis-
tribution to be estimated as well as the inter- and intra-
patient variability in these parameters. In these models it
can be determined how hypothermia affects drug distri-
bution, metabolism and excretion. Furthermore it can be
evaluated whether specific patient factors (demographi-
cal, severity of asphyxia or end organ dysfunction/multi
organ dysfunction) are related to changes in drug behav-
iour. Since PK models will be developed for neonates
allometric scaling and maturation of PK parameters will
be taken into account.
With a population PK model available different dosing
schedules can be simulated in order to obtain adequate
drug exposure during controlled hypothermia. The
NONMEM-analyses will be performed in the Clinical
Pharmacology Unit of the Hospital Pharmacy of the Aca-
demic Medical Center in Amsterdam (Prof. Dr R.A.A.
Mathôt) and at the Department of Clinical Pharmacy of
the University Medical Centre Utrecht in Utrecht.
Pharmacodynamic measures
Concentration effect relationships will be studied by
NONMEM analyses as well. The following PD mea-
sures/endpoints will be used: successful seizure control
(by anti-epileptic medication), adequate sedation or pain
control by newborn stress scales (sedatives), adequate
treatment of perinatal infection shown by negative repeat
blood culture and correlation with MIC- values of cultured
microorganisms. Also toxic side effects on end organs will
be evaluated. (E.g. hearing damage caused by aminoglyco-
side medication evaluated by newborn hearing screening
(ALGO-screening) or in case of abnormal ALGO; by
brainstem auditory evoked potential investigation.).
Imaging studies & follow-up
A neonatal cerebral MRI will be performed in all patients
as part of standard clinical care after the cooling proced-
ure or if clinically indicated at an earlier stage. T1-and
T2 weighted images and DWI (Diffusion Weighted
Imaging) will be obtained in each patient. The MRI
images will be evaluated centrally by skilled neonatolo-
gists and neuroradiologists. Long term follow-up of
asphyxiated neonates is part of the standard care proto-
col of the Dutch Working Group of Neonatal follow-up.
Long term outcome will be assessed by neurodevelop-
mental testing at the ages of 6 months, 1 and 2 years.
When these long term outcomes become available, their
association with perinatal pharmacological and clinical
data will be investigated.
Sample size considerations
A formal power calculation cannot be performed as in-
formation is lacking. As a result our study has an ex-
plorative character. Nevertheless, as a rule of thumb data
of at least 20 patients per investigated drug are consid-
ered to be sufficient to develop a population PK model.
Runtime
The total time for this study is three years. Inclusion will
be stopped if the number of patients needed per drug (or
medication group) has been reached. Each patient will
followed-up until the age of 2 years according to the
standard care protocol.
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